Dr. Abraham NYSKA
He has more than 40 years’ experience in pre-clinical risk assessment of chemicals, drugs, medical devices and stem cells. Since 1999 he has served as Expert in Toxicologic Pathology at the American National Toxicology Program (NTP) of the National Institute of Health (NIH). Since 2005 he is serving as a consultant in Toxicology and Toxicologic Pathology, Pharmaceutical, CRO’s, and Federal institutes (Israel, Europe, Japan, India, USA). He is member of the international expert committees for harmonization of terminologies in toxicologic pathology (IN-HAND initiative).
Deeply engaged in the introduction and application of newly developed, self-containing imaging systems, which provide an efficient and cost-effective means to rapidly obtain in- vivo and ex-vivo magnetic resonance imaging images to improve how we perform toxicology and toxicologic pathology.
Dr. Nyska is involved in the application of state-of the art digital telepathology solutions for real time peer review and pathology working group applications in the field of toxicologic pathology.
He is an associated editor of “Toxicologic Pathology”; and co-author of more than 420 peer reviewed publications and/or chapters in books.
Dr. Peter WEBBORN
He has worked in the UK, US and Sweden. His particular areas on interest include prediction of Pharmacokinetic properties, physicochemical properties as determinants of drug clearance and distribution, and the use of PKPD modelling to help understand therapeutic utility.
From 2011 he led the internalisation, development, and integration of AstraZeneca’s mass spectrometry imaging capability, bringing new insights to projects about drug distribution in relation to biological effects.
In 2016 he left AstraZeneca and now works as an independent consultant, supporting Biotech and Pharma.
He has published over 30 papers and was a recipient of the Royal Society of Chemistry, Malcolm Campbell medal in 2013 for his work on the discovery of Brilinta.